Anakinra: A New Weapon in the Fight Against COVID-19

A randomized clinical trial was conducted to assess the efficacy and safety of anakinra in treating severe COVID-19 pneumonia and hyperinflammation. The trial involved 179 adult patients who were assigned to either anakinra plus standard of care or standard of care alone. The primary outcome was the proportion of patients not requiring mechanical ventilation up to 15 days after treatment initiation. The results showed that anakinra did not prevent the need for mechanical ventilation or reduce mortality risk compared with standard of care alone